- Home
- ITUB vs REGN Comparison
ITUB vs REGN Comparison
Compare ITUB & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ITUB | REGN |
|---|---|---|
| Founded | 1924 | 1988 |
| Country | Brazil | United States |
| Employees | 92470 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 85.9B | 73.2B |
| IPO Year | 2002 | 1995 |
Fundamental Metrics
Financial Performance| Metric | ITUB | REGN |
|---|---|---|
| Price | $7.83 | $603.31 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 25 |
| Target Price | $9.00 | ★ $830.16 |
| AVG Volume (30 Days) | ★ 21.0M | 984.1K |
| Earning Date | 05-05-2026 | 04-29-2026 |
| Dividend Yield | ★ 6.12% | 0.55% |
| EPS Growth | N/A | ★ 8.19 |
| EPS | N/A | ★ 6.75 |
| Revenue | N/A | ★ $5,872,227,000.00 |
| Revenue This Year | $46.47 | $12.45 |
| Revenue Next Year | $8.14 | $10.13 |
| P/E Ratio | ★ $12.60 | $90.01 |
| Revenue Growth | N/A | ★ 20.82 |
| 52 Week Low | $6.11 | $518.90 |
| 52 Week High | $9.60 | $821.11 |
Technical Indicators
Market Signals| Indicator | ITUB | REGN |
|---|---|---|
| Relative Strength Index (RSI) | 45.51 | 37.91 |
| Support Level | $7.75 | $591.52 |
| Resistance Level | $7.86 | $618.01 |
| Average True Range (ATR) | 0.18 | 15.75 |
| MACD | 0.05 | 3.37 |
| Stochastic Oscillator | 48.19 | 37.36 |
Price Performance
Historical ComparisonAbout ITUB Itau Unibanco Banco Holding SA (Each repstg 500 Preferred shares)
Itaú Unibanco is the largest privately held bank in Brazil, the result of the 2008 merger between Banco Itaú and Unibanco. In addition to Brazil, the bank has significant operations in Chile, Colombia, Argentina, Uruguay, and Paraguay. Itaú's commercial and consumer loans account for 35% and 43% of the bank's total loans, respectively, while foreign loans account for 22% of its portfolio as of the end of 2025. The bank also operates the fifth-largest insurer in Brazil and is the second-largest asset manager in the country, giving it broad reach over the Brazilian financial system.
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.